Perioperative posterior cervical muscle plane block decreased numerical pain rating scores vs anesthesia alone in posterior cervical spine surgery.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Palantir’s Q4 revealed a 45% operating margin and 36% revenue growth, but its shares reflect over five years’ growth already.

According to published results, a novel opioid-free pathway may provide noninferior pain management compared with an opioid-containing pathway during the perioperative period in patients undergoing ...

UBS maintained a 'Buy' rating on Swiggy stock with a target price of Rs 510, while Macquarie maintained an 'Underperform' ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Dishes out pain Saturday ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Asian Paints' consolidated net profit attributable to the owners of the company declined 23.3 per cent year-on-year (Y-o-Y) ...

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report sent to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s ...